CBIO - NASDAQ

Crescent Biopharma, Inc.

Crescent Biopharma, Inc.

CBIO·NASDAQ

$17.95

+5.6%
HealthcareBiotechnology

Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$495.05M
EPS-14.7800
P/E Ratio-1.21
Earnings Date07/30/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

Crescent Biopharma, Inc.

Crescent Biopharma, Inc. Earnings Call Transcripts

CBIO · NASDAQ

Related Guides

Blog Categories

Continue your CBIO research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.